Please login to the form below

Not currently logged in
Email:
Password:

Ionis

This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH. Will acquire the US pharma group’s antisense drug in a deal valued up to $330m. ... Almost a year after giving up on a non-alcoholic steatohepatitis (NASH) drug licensed from Regulus, AstraZeneca has

Latest news

  • AZ adds another Ionis drug in $330m kidney disease deal AZ adds another Ionis drug in $330m kidney disease deal

    AZ adds another Ionis drug in $330m kidney disease deal. The candidate targets a genetically associated form of the condition. ... AstraZeneca has signed another licensing deal with antisense specialist Ionis, this time paying $30m upfront and $300m in

  • Biogen cuts $217m deal for Karyopharm neurology drug Biogen cuts $217m deal for Karyopharm neurology drug

    Biogen is already focusing on ALS with one of its other collaborations, a pair-up with antisense specialist Ionis targeting genetic subsets of ALS such as patients with the SOD1 mutation. ... Spinraza - licensed from Ionis - brought in a whopping $363m

  • FDA lifts clinical hold on Sanofi’s haemophilia drug FDA lifts clinical hold on Sanofi’s haemophilia drug

    on track and hit its targets in a phase III trial reported in September – and according to some analysts seems to have outperformed a rival therapy from Ionis Pharma.

  • Alnylam takes off on APOLLO trial results Alnylam takes off on APOLLO trial results

    Alnylam's success in the phase III trial proved to be a dampener for Ionis Pharmaceuticals, which is developing antisense-based drug inotersen for this type of familial amyloid polyneuropathy (FAP). ... The company shares fell yesterday on the APOLLO

  • Ionis must go it alone as GSK ditches polyneuropathy drug Ionis must go it alone as GSK ditches polyneuropathy drug

    Ionis must go it alone as GSK ditches polyneuropathy drug. Inotersen’s side effects prompts pharma giant to relinquish rights. ... another Ionis candidate - IONIS-FB-LRX for complement-mediated diseases in early-stage clinical testing.

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... As part of the agreement Ionis will also expand the collaboration

  • Deal Watch January 2017 Deal Watch January 2017

    As you sow, so shall you reap The use of options is remaining widespread as noted in the Novartis deal with Ionis and Akcea. ... 1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.

  • Deal Watch August 2016 Deal Watch August 2016

    95. Ionis (US). Biogen (US). Exercise option . Nusinersen, in phase III for treatment for spinal muscular atrophy.

  • Deal Watch May 2016 Deal Watch May 2016

    This month GSK elected not to currently proceed with its option to Ionis Pharmaceuticals' IONIS-TTRrx, which was about to enter into phase 3 clinical development. ... The knock on effect for Ionis shares was a dip by a significant 40%.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics